海利生物增值9倍并购的企业踩雷了,第一大客户竟是未成立的公司

Core Insights - The acquisition of Rui Sheng Biological by Haili Biological has led to unexpected valuation adjustments, with Rui Sheng's valuation dropping from 1.7 billion RMB to 974 million RMB due to performance declines [7][18] - The presence of a company that was not yet established as a major client of Rui Sheng raises questions about the accuracy of financial disclosures [9][11] - The investigation revealed inconsistencies in client relationships and potential issues with financial reporting practices [20][21] Group 1 - Haili Biological acquired 55% of Rui Sheng Biological for 935 million RMB, resulting in a valuation increase of 952% at the time of acquisition [7] - Rui Sheng Biological's valuation was subsequently revised downwards due to declining performance, with a projected valuation of 974 million RMB by June 2025 [7][18] - The company claims to be a leading player in the market for natural calcined bone repair materials, particularly in dental applications [7] Group 2 - Wuhan He Mu Medical Technology, a client listed by Rui Sheng, was found to have been established only in April 2023, raising questions about its status as a major client [10][11] - The explanation provided by Haili Biological regarding the client relationship was deemed insufficient by financial experts, suggesting potential financial misrepresentation [11][18] - The investigation into client relationships revealed that actual business dealings may have been misrepresented, with claims of shared operations between different entities [13][15] Group 3 - The performance of Rui Sheng Biological has been adversely affected by increased competition and price wars, leading to a significant drop in revenue and profit margins [42][43] - The company reported a revenue of 26.77 million RMB and a net profit of 9.29 million RMB in Q3 2025, indicating a substantial decline compared to previous quarters [42] - Haili Biological plans to expand its operations by acquiring stakes in dental chain companies, which is expected to positively impact its financial performance in 2026 [43][44]

HILE-海利生物增值9倍并购的企业踩雷了,第一大客户竟是未成立的公司 - Reportify